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Summary
Background People living with HIV are at an increased risk of fatal outcome when admitted to hospital for severe 
COVID-19 compared with HIV-negative individuals. We aimed to assess safety and immunogenicity of the 
ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV and HIV-negative individuals in South Africa.
Methods In this ongoing, double-blind, placebo-controlled, phase 1B/2A trial (COV005), people with HIV and 
HIV-negative participants aged 18−65 years were enrolled at seven South African locations and were randomly 
allocated (1:1) with full allocation concealment to receive a prime-boost regimen of ChAdOx1 nCoV-19, with two doses 
given 28 days apart. Eligibility criteria for people with HIV included being on antiretroviral therapy for at least 
3 months, with a plasma HIV viral load of less than 1000 copies per mL. In this interim analysis, safety and 
reactogenicity was assessed in all individuals who received at least one dose of ChAdOx1 nCov 19 between enrolment 
and Jan 15, 2021. Primary immunogenicity analyses included participants who received two doses of trial intervention 
and were SARS-CoV-2 seronegative at baseline. This trial is registered with ClinicalTrials.gov, NCT04444674, and the 
Pan African Clinicals Trials Registry, PACTR202006922165132.
Findings Between June 24 and Nov 12, 2020, 104 people with HIV and 70 HIV-negative individuals were enrolled. 
102 people with HIV (52 vaccine; 50 placebo) and 56 HIV-negative participants (28 vaccine; 28 placebo) received the 
priming dose, 100 people with HIV (51 vaccine; 49 placebo) and 46 HIV-negative participants (24 vaccine; 22 placebo) 
received two doses (priming and booster). In participants seronegative for SARS-CoV-2 at baseline, there were 
164 adverse events in those with HIV (86 vaccine; 78 placebo) and 237 in HIV-negative participants (95 vaccine; 
142 placebo). Of seven serious adverse events, one severe fever in a HIV-negative participant was definitely related 
to trial intervention and one severely elevated alanine aminotranferase in a participant with HIV was unlikely 
related; five others were deemed unrelated. One person with HIV died (unlikely related). People with HIV and 
HIV-negative participants showed vaccine-induced serum IgG responses against wild-type Wuhan-1 Asp614Gly 
(also known as D614G). For participants seronegative for SARS-CoV-2 antigens at baseline, full-length spike 
geometric mean concentration (GMC) at day 28 was 163·7 binding antibody units (BAU)/mL (95% CI 89·9–298·1) 
for people with HIV (n=36) and 112·3 BAU/mL (61·7–204·4) for HIV-negative participants (n=23), with a rising 
day 42 GMC booster response in both groups. Baseline SARS-CoV-2 seropositive people with HIV demonstrated 
higher antibody responses after each vaccine dose than did people with HIV who were seronegative at baseline. 
High-level binding antibody cross-reactivity for the full-length spike and receptor-binding domain of the 
beta variant (B.1.351) was seen regardless of HIV status. In people with HIV who developed high titre responses, 
predominantly those who were receptor-binding domain seropositive at enrolment, neutralising activity against 
beta was retained.
Interpretation ChAdOx1 nCoV-19 was well tolerated, showing favourable safety and immunogenicity in people with 
HIV, including heightened immunogenicity in SARS-CoV-2 baseline-seropositive participants. People with HIV 
showed cross-reactive binding antibodies to the beta variant and Asp614Gly wild-type, and high responders retained 
neutralisation against beta.
Funding The Bill & Melinda Gates Foundation, South African Medical Research Council, UK Research and Innovation, 
UK National Institute for Health Research, and the South African Medical Research Council.
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Introduction
Vaccines against SARS-CoV-2 are being deployed 
globally to prevent COVID-19. Included among the first-
generation COVID-19 vaccines authorised for emergency 
use is ChAdOx1 nCoV-19 (AZD1222), a non-replicating 
chimpanzee adenovirus-vectored vaccine that expresses 
the full-length spike (FLS) glycoprotein gene of SARS-
CoV-2.1,2 Safety and efficacy of ChAdOx1 nCoV-19 in 
clinical trials have been demonstrated,3 and immuno-
genicity studies have shown that ChAdOx1 nCoV-19 
induces antibody responses specific to the spike protein, 
and to the receptor-binding domain (RBD) of the spike 
protein 28 days after the first dose in all adults.4
The SARS-CoV-2 spike genome has accumulated 
mutations resulting in the emergence of variants, 
including the beta (B.1.351) lineage first identified in 
South Africa.5 There are few published reports on the 
safety and immunogenicity of ChAdOx1 nCoV-19 and 
other COVID-19 vaccines in people with HIV, and even 
fewer reports specific to people living in Africa.6 
Compared with HIV-negative individuals, people with 
HIV are at greater risk for infectious diseases, such as 
influenza, including during antiretroviral therapy (ART),7 
and are at higher risk of a fatal outcome when admitted 
to hospital for severe COVID-19.8 Risk factors for severe 
COVID-19 in people with HIV include more advanced 
stage of HIV/AIDS, the HIV-1 infection not being virally 
suppressed, and CD4 counts below 500 cells per µL.
The US Centers for Disease Control and Prevention 
advises that people with HIV can choose to be vaccinated 
against COVID-19, but might have reduced immune 
responses to the vaccine,9 whereas WHO recommends 
that people with HIV should be immunised with 
COVID-19 vaccines.10,11 Although there are an estimated 
38 million people with HIV globally, there is limited 
knowledge on the safety and immunogenicity of COVID-19 
vaccines in this population.12,13 This disparity is particularly 
pertinent to sub-Saharan Africa, where more than 80% of 
the global population of people with HIV live, including 
7·5 million in South Africa.13
Here, we report interim results from a multicentre, 
randomised, double-blind, placebo-controlled, phase 1B/2A 
trial (COV005) assessing the safety and immunogenicity of 




This interim analysis of the ongoing, adaptive, random-
ised, double-blind, placebo-controlled, phase 1B/2A trial 
(COV005) assessed the safety and immunogenicity of the 
ChAdOx1 nCoV-19 vaccine in South Africa. Study details 
were published previously.6 Briefly, trial enrolment began 
on June 24, 2020, and is ongoing in seven South African 
sites (research centres, hospitals, and clinical trials centre) 
in accordance with the principles of the Declaration of 
Helsinki and Good Clinical Practice Guidelines.14 The 
COV005 study was approved by the South African Health 
Products Regulatory Authority and the ethics committees 
of the University of Oxford, University of the Witwatersrand, 
Stellenbosch University, and University of Cape Town. The 
trial protocol (version 6.0) is available online.15
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Research in context
Evidence before this study
We searched PubMed for peer-reviewed articles published 
between Jan 1, 2019, and June 29, 2021, with no language 
restrictions, using the terms “Safety” AND “COVID-19” AND 
“vaccine” AND “HIV”. Our search returned one peer-reviewed 
study that explored safety and immunogenicity of the 
ChAdOx1 nCoV-19 (AZD1222) vaccine in people with HIV in 
the UK, findings of which deemed the vaccine to be safe and 
immunogenic in people with HIV that are well controlled on 
antiretroviral therapy. We did not find any reports that 
evaluated safety and immunogenicity of COVID-19 vaccines in 
this population in Africa.
Added value of this study
This interim analysis of the COV005 study provides novel 
evidence of the safety and immunogenicity of the ChAdOx1 
nCoV-19 vaccine in people with and without HIV in 
South Africa. Because people with HIV are at greater risk for 
infectious diseases and are at higher risk of a fatal outcome 
when admitted to hospital for severe COVID-19 than are the 
general population, our results provide reassurance of 
protection following ChAdOx1 nCoV-19 vaccination in this 
population. Furthermore, our results show that high 
neutralising antibody titres in people with HIV who were 
seropositive for SARS-CoV-2 at baseline were associated with a 
preserved ability to neutralise the beta (B.1.351) variant of 
concern, though at reduced titres; which was not evident in 
vaccinees without previous SARS-CoV-2 infection. This finding 
is of particular value in areas with high burdens of previous 
SARS-CoV-2 infection.
Implications of all the available evidence
These interim findings are vital for informing the clinical 
management of people with HIV during the COVID-19 
pandemic. Our analysis suggests that priming by natural 
infection with the ancestral virus Asp614Gly wild-type before 
vaccination with ChAdOx1 nCoV-19 could lead to heightened 
neutralising antibody titres with relative preservation of 
activity against the beta variant compared with those who were 
SARS-CoV-2 seronegative when receiving the first vaccine dose.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
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Participants
Volunteers from the general community were invited to 
participate in the study by way of public announcement 
and advertising on social media. Eligible participants were 
healthy adults aged 18–65 years with and without HIV in 
South Africa. HIV status was tested before enrolment. As 
this was a phase 1B/2A trial, inclusion criteria for people 
with HIV were restrictive, including those on stable ART 
for at least 3 months and required an HIV-1 viral load of 
less than 1000 copies per mL within 2 weeks of 
randomisation. All participants were required to test 
seronegative for hepatitis B surface antigen. Participants 
with abnormalities (grade ≥2) in full blood count, urea, 
and electrolyte tests, or liver function tests were excluded, 
according to the Division of AIDS Grading Criteria 
(version 2.1, July 2017). Full exclusion and inclusion 
criteria are provided in the trial protocol.15 All participants 
were fully informed about trial procedures and possible 
risks before giving written informed consent.
Randomisation and masking
Details of randomisation have been previously published.14 
Briefly, people with HIV and HIV-negative participants 
were randomly assigned (1:1), via a computer-generated 
system, with full allocation concealment, to receive 
two intramuscular injections of either ChAdOx1 nCoV-19 
(vaccine group) or saline placebo (0·9% sodium chloride; 
placebo group), given 28 days apart.
Clinical procedures
As previously described,6 between June 24, 2020, and 
July 29, 2020, we enrolled a cohort of 70 HIV-negative 
individuals (group 1) for intensive safety and immuno-
genicity monitoring, followed by wider enrolment of 
HIV-negative individuals (group 2) for further safety, 
immunogenicity, and efficacy assessment. Group 2 data 
are described elsewhere.15 Between Aug 17, 2020, and 
Nov 12, 2020, we enrolled people with HIV (group 3) 
for intensive safety and immunogenicity assessment. 
This interim analysis compares data obtained from 
group 1 (HIV-negative individuals) and group 3 (people 
with HIV), which both involved intensive immuno-
genicity monitoring.
The original protocol (version 1.0) included a nasal 
swab to test for SARS-CoV-2 infection at the time 
of randomisation, irrespective of symptomatology, and 
blood samples taken for serology analysis of SARS-CoV-2 
infection. After 24 participants were enrolled in group 1, 
seven (29%) participants had positive PCR tests for 
SARS-CoV-2 on nasal swabs collected on the day of 
randomisation. The protocol was, therefore, amended to 
include screening for SARS-CoV-2 via PCR within 96 h of 
randomisation, and a positive SARS-CoV-2 PCR test was 
added as an exclusion criterion, implemented before 
enrolment of people with HIV began.
For group 1, the sample size was increased from 
50 to 70 to replace individuals who tested positive for 
SARS-CoV-2 infection at randomisation during the initial 
phase of enrolment. For group 3, the sample size was 
increased from 50 to 100 owing to a high (35–45%) level 
of SARS-CoV-2 infection opportunistically identified 
in residual blood samples from people with HIV 
in South Africa as the first wave was subsiding.16 We 
estimated that the increase in sample size would result 
in about 50 individuals in group 1 and 70 in group 3 who 
would remain seronegative for COVID-19 until 2 weeks 
after the booster dose and, therefore, evaluable for the 
main immunogenicity analysis that was restricted to 
those who were SARS-CoV-2 naive at enrolment.
ChAdOx1 nCoV-19 is formulated at 5 × 10¹⁰ virus 
particles per dose. In this trial, three different batches 
of ChAdOx1 nCoV-19 were manufactured and used as 
detailed in the appendix (pp 1–2). We used PCR to test for 
SARS-CoV-2 infection at baseline and throughout the 
trial as previously described.15
Laboratory procedures
Expression plasmids encoding SARS-CoV-2 FLS and 
RBD were obtained from Florian Krammer (Mount Sinai, 
NY, USA). The recombinant FLS and RBD proteins from 
either the Asp614Gly (also known as D614G) wild-type or 
beta SARS-CoV-2 variant were expressed and purified as 
described previously17 and were coupled to magnetic 
microspheres (Bio-Rad, Philadelphia, PA, USA) using a 
two-step carbodiimide reaction.18
We analysed immunogenicity on day 0, before 
administration of the first placebo or vaccine dose 
(priming dose), on day 28 after the priming dose, the day 
that the second dose of placebo or vaccine (booster dose) 
was administered, and on day 42 (14 days after the booster). 
Singleplex bead-based immunoassays were developed on 
the Luminex platform to quantitatively measure serum 
IgG binding to FLS and RBD. We developed an in-house 
reference serum by pooling convalescent serum from 
adults with COVID-19. This interim reference serum was 
calibrated against a research reagent for anti-SARS-CoV-2 
antibody (code 20/130 supplied by National Institute 
for Biological Standards and Control, Herts, UK). This 
research reagent for SARS-CoV-2 RNA was used for the 
development and evaluation of serological assays for the 
detection of antibodies against SARS-CoV-2. Details of 
the binding antibody units (BAU) for viral components 
can be found online. The BAU assigned to the in-house 
See Online for appendix
For more on the BAU units see 
https://www.nibsc.org/
Figure 1: Study profile, stratified by SARS-CoV-2 serostatus
27 participants (21 HIV-negative people and six people with HIV) were excluded 
from this interim analysis because of a positive SARS-CoV-2 PCR test within the 
trial period. Three participants were excluded from the immunogenicity analysis 
owing to an absence of baseline serology. 12 participants (one withdrawn and 
11 positive SARS-CoV-2 PCR tests) did not receive a booster dose. 
Three participants were excluded from analysis at day 42 as they were lost to 
follow-up. FLS=full length spike. RBD=receptor-binding domain. *One or more 
samples were not determined due to insufficient sample volume, haemolysis, or 
sample not collected. 
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reference serum were 1242 BAU/mL for RBD IgG and 
2819 BAU/mL for FLS IgG. Luminex assay sensitivity and 
specificity are described in the appendix (p 1).
Humoral responses at baseline and after vaccination 
were assessed with ELISA-based antibody binding assays 
to recombinant SARS-CoV-2 RBD and FLS proteins 
from Asp614Gly wild-type and the beta variant as 
previously described.18 Additional details are given in the 
appendix (p 1).
To determine serum concentrations of SARS-CoV-2 
neutralising antibodies, we used two pseudovirus 
neutralisation assays. Samples from HIV-negative 
participants were tested using a SARS-CoV-2 Asp614Gly 
wild-type neutralisation assay at the National Institute for 
Overall 
(n=161)













Median (IQR) age, years 37 (31–44) 32 (25–42) 31 (26–42) 34 (23–41) 40 (33–46) 41 (36–46) 37 (32–45)
Sex
Female 98 (61%) 22 (38%) 10 (34%) 12 (41%) 76 (74%) 40 (78%) 36 (69%)
Male 63 (39%) 36 (62%) 19 (66%) 17 (59%) 27 (26%) 11 (22%) 16 (31%)
Race
Black 160 (99%) 58 (100%) 29 (100%) 29 (100%) 102 (99%) 51 (100%) 51 (98%)
White 1 (1%) 0 0 0 1 (1%) 0 1 (2%)
Body-mass index, kg/m²
<18 12 (8%) 7 (12%) 4 (14%) 3 (10%) 5 (5%) 1 (2%) 4 (8%)
18–24·9 68 (42%) 26 (45%) 15 (52%) 11 (38%) 42 (41%) 18 (35%) 24 (46%)
25–29·9 46 (29%) 13 (22%) 4 (14%) 9 (31%) 33 (32%) 16 (31%) 17 (33%)
30–39·9 35 (22%) 12 (21%) 6 (21%) 6 (21%) 23 (22%) 16 (31%) 7 (14%)
Current smoker 61 (38%) 27 (47%) 12 (41%) 15 (52%) 34 (33%) 16 (31%) 18 (35%)
Current alcohol drinker 72 (45%) 25 (43%) 13 (45%) 12 (41%) 47 (46%) 21 (41%) 26 (50%)
Health-care worker 3 (2%) 1 (2%) 1 (3%) 0 2 (2%) 1 (2%) 1 (2%)
Hypertension 12 (8%) 1 (2%) 0 1 (3%) 11 (11%) 7 (14%) 4 (8%)
Chronic respiratory disease 16 (10%) 0 0 0 16 (16%) 10 (20%) 6 (12%)
HbA1c
Low 12 (8%) 2 (3%) 0 2 (7%) 10 (10%) 5 (10%) 5 (10%)
Normal 145 (90%) 53 (91%) 26 (90%) 27 (93%) 92 (89%) 46 (90%) 46 (89%)
High 4 (3%) 3 (5%) 3 (10%) 0 1 (1%) 0 1 (2%)
ART use*
NNRTI and two NRTIs NA NA NA NA 57 (76%) 29 (74%) 28 (78%)
INSTI and two NRTIs NA NA NA NA 11 (15%) 5 (13%) 6 (17%)
Boosted PI and one NRTI NA NA NA NA 4 (5%) 3 (8%) 1 (3%)
Boosted PI and two NRTIs NA NA NA NA 3 (4%) 2 (5%) 1 (3%)
Years on ART
<1 NA NA NA NA 9 (12%) 4 (10%) 5 (14%)
1 to <5 NA NA NA NA 28 (37%) 12 (31%) 16 (44%)
≥5 NA NA NA NA 38 (51%) 23 (59%) 15 (42%)






Median (IQR) CD4 percentage NA NA NA NA 36 (30–41) 36 (29–41) 37 (32–41)
Viral load <50 copies per mL 27 (75%) NA NA NA 27 (75%) 18 (82%) 9 (64%)
Median (IQR) time between doses, days 28 (27–28) 28 (28–28) 28 (28–28) 28 (28–28) 28 (25–28) 28 (26–28) 28 (23–28)
Median (IQR) time post-boost, days 14 (14–14) 14 (14–15) 14 (14–14) 14 (14–15) 14 (14–14) 14 (14–14) 14 (14–14)
Data are n (%) unless otherwise stated. Data exclude patients who were SARS-CoV-2 seropositive at baseline and include patients with no baseline serology available. 
ART=antiretroviral therapy. HbA1c=glycated haemoglobin. INSTI=integrase strand transfer inhibitor. NA=not applicable. NNRTI=non-nucleoside reverse transcriptase inhibitor. 
NRTI=nucleoside or nucleotide reverse transcriptase inhibitors. PI=protease inhibitors. *Most participants (75%) were receiving an efavirenz-based regimen, 15% were receiving 
a dolutegravir-based regimen with two NRTIs (tenofovir and lamivudine or emtricitabine), and one participant received zidovidine and lamivudine. The remaining participants 
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Communicable Diseases (South Africa) using pseudo-
viruses produced by cotransfection with a lentiviral 
backbone (HIV-1 pNL4.luc) as previously described.17 For 
samples from people with HIV, which might be affected 
by antiretroviral drugs, samples were first screened 
for antiretroviral-mediated background activity using 
murine leukaemia virus (MLV) envelope pseudotyped 
viruses in an MLV backbone.19 Of 51 samples, 18 (35%) 
showing background presumed to be mediated by 
antiretrovirals were excluded from further testing; 
acceptable samples were tested using a SARS-CoV-2-
specific microneutralisation assay in the same MLV 
backbone expressing Asp614Gly wild-type. Comparison 
of the two assays on 56 samples showed high levels of 
concordance (r=0·8561, p<0·0001) for Asp614Gly wild-
type-mediated neutralisation between these two assays 
(appendix p 31). We used a subset of 40 samples, which 
were shown to be seropositive for Asp614Gly wild-type 
FLS at day 42, to evaluate neutralisation against the 
beta variant. IgG was purified from 100 μL of plasma 
using protein A, and the eluate was normalised back to 
input volumes. IgG was tested against both Asp614Gly 
wild-type and the beta variant. High levels of concordance 
(r=0·9165, p=0·0054) between plasma-mediated and IgG-
mediated neutral isation of Asp614Gly wild-type was seen 
in 23 samples (appendix p 32).
Outcomes
The primary endpoint in both HIV-negative participants 
and people with HIV was the safety, tolerability, and 
reactogenicity profile of ChAdOx1 nCoV-19. Tolerability 
was assessed by local and systemic reactogenicity and 
adverse events, stratified by SARS-CoV-2 serostatus 
at enrolment. In people with HIV, the coprimary endpoint 
was cellular and humoral immunogenicity of 
ChAdOx1 nCoV-19, as assessed by quantification of serum 
antibody (IgG) to SARS-CoV-2 FLS protein, RBD, and 
virus neutralising antibody assays against pseudotyped 
SARS-CoV-2 virus, stratified by SARS-CoV-2 serostatus 
at enrolment. The coprimary endpoint of efficacy of 
ChAdOx1 nCoV-19 against COVID-19 in HIV-negative 
participants is reported elsewhere.6
Coprimary endpoints and unsolicited adverse events 
were assessed at days 7 and 28 after vaccination, 
respectively.
Baseline assessments included review of inclusion 
and exclusion criteria, medical history, vital sign 
measurements, history-directed clinical examination, 
and collection of serum for SARS-CoV-2 serology. All 
participants had SARS-CoV-2 PCR testing within 96 h 
of randomisation, and on days 7, 14, 28, 35, 42, and 56 
after randomisation. Baseline SARS-CoV-2 serostatus 
was determined by testing participant serum with a 
colorimetric, plate-based RBD IgG ELISA assay, as 
previously described.17 Participants were also reminded 
to contact the trial site if they experienced specific 
symptoms associated with COVID-19.
In this interim analysis, we report solicited adverse 
events (reactogenicity) within 7 days of each vaccine or 
placebo dose, and unsolicited adverse events during the 
study period (28 days). Safety evaluations included analysis 
of full blood count, urine, and electrolytes, and liver 
function tests, which were all assessed before randomisa-
tion, on days 3 and 7 after randomisation, on the day the 
booster dose was given, and on days 14 and 28 after the 
booster dose. Follow-up will continue for 12 months after 
enrolment. This interim analysis includes adverse event 
data reported by Jan 15, 2021 (inclusive).
Statistical analysis
The safety analysis set, used for safety and reactogenicity 
analyses, included all randomised individuals who 
received at least one dose of trial intervention between 
enrolment and Jan 15, 2021. Primary immunogenicity 
analyses included partici pants who received two doses of 
trial intervention and were SARS-CoV-2 seronegative at 
baseline, with further analyses done in those who were 
RBD seropositive at baseline. Immunogenicity analyses 
were restricted to individuals who were not SARS-CoV-2 
seropositive, with seropositive individuals included up 
until the time of infection at any time between day 0 and 
day 42. Summary statistics for demographic and clinical 
characteristics are reported as medians (IQR) for 
quantitative measurements and as counts and proportions 
for categorical variables. Antibody concentrations or titres 
are summarised as geometric mean concentrations 
(GMCs) and geometric mean titres (GMTs), respectively. 
We calculated 95% CIs for GMCs or GMTs by back 
transforming the 95% CI for log antibody concentrations 
or titres. We used a normal approximation method to 
calculate 95% CIs for proportions.
For the primary safety objective, the sample size was 
25 participants per comparator group. For a serious 
event with a 0·01 rate of occurrence, the probability 
that zero participants will experience this event is 
0·778 in each group. For the primary immunogenicity 
endpoint, a sample size of 25 per group would 
have 80% power to detect a 48% difference in response 
rates between two groups, if the true response rate in 
the unvaccinated group was 10%. Our sample size 
calculations were based on Fisher’s exact test to compare 
the response rate between groups. Power calculations for 
this trial have been published.15 Additional post-hoc 
analyses examined immunogenicity in people with HIV 
who were SARS-CoV-2 seropositive before their first 
vaccine dose.
We used R (version 4.02) for all statistical analyses.20 
The COV005 study is registered with ClinicalTrials.gov, 
NCT04444674, and the Pan African Clinical Trials 
Registry, PACTR202006922165132.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
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writing of the report. AstraZeneca reviewed the data 
from the trial and the final manuscript before submission 
and funded writing and editing assistance, but the 
academic authors retained editorial control.
Results
We enrolled 104 people with HIV (between Aug 17 and 
Nov 12, 2020) and 70 HIV-negative individuals (between 
June 24 and July 29, 2020) to the intensive safety and 
immunogenicity cohort. One person with HIV and 
12 HIV-negative participants had positive SARS-CoV-2 
PCR tests at randomisation and were excluded from 
all analyses. One further person with HIV and two HIV-
negative participants without baseline serology were 
excluded from immunogenicity analyses. 35 (22%) of 
158 participants, including 32 (31%) of 102 people with 
HIV had serological evidence of previous SARS-CoV-2 
infection (RBD IgG positive) before receipt of the 
priming dose of study treatment and were enrolled, as a 
result of high infection burden within the population. 
After excluding participants with positive SARS-CoV-2 
PCR tests or unavailable serology results at baseline, 
56 HIV-negative participants (28 vaccine; 28 placebo) and 
102 people with HIV (52 vaccine; 50 placebo) received the 
priming dose of trial intervention (figure 1). 32 (31%) of 
102 people with HIV and three (5%) of 56 HIV-negative 
participants tested seropositive (RBD IgG positive) for 
SARS-CoV-2 at randomisation; this difference is probably 
a result of different enrolment dates, as the former were 
enrolled after the first epidemic wave of COVID-19 and 
were, therefore, more likely to have been exposed to 
SARS-CoV-2.
Between the priming dose and before day 42 (14 days 
post-booster dose), an additional five people with HIV 
and nine HIV-negative participants were excluded from 
further analyses because of positive SARS-CoV-2 
PCR tests (figure 1). One further HIV-negative participant 
in the placebo group was withdrawn from the trial 
(between doses) because of previously undisclosed 
history of mental illness, and three people with HIV 
(one placebo, two vaccine) missed day 42 trial visits.
In the overall population, excluding participants who 
had a positive SARS-CoV-2 PCR test but including 
participants with no baseline serology, 62% of HIV-
negative participants were men, compared with 26% of 
people with HIV. 99% were Black (table). The median 
age of HIV-negative participants was lower than that of 
people with HIV. HIV-negative participants had a lower 
prevalence of underlying hypertension and chronic 
respiratory conditions, compared with people with HIV. 
The proportion of individuals with a body-mass index of 
30·0–39·9 kg/m² was similar between HIV-negative 
participants and people with HIV. People with HIV 
were stable on ART, with a median CD4 count of 
695 cells per µL, a CD4 percentage of 36%, and 
75% of participants had viral loads of less than 50 copies 
per mL (table).
The demographic characteristics of participants who 
were SARS-CoV-2 seronegative at the time of randomi-
sation and, therefore, eligible for inclusion in our 
post-booster-dose immune response analyses, and the 
demographic characteristics of participants who were 
SARS-CoV-2 seropositive at randomisation, were similar 
to those of the overall population (appendix pp 3–5). 
Demographic characteristics of people with HIV are in 
the appendix (p 6).
In HIV-negative participants and people with HIV, 
tenderness, hardness, bruising, and itching at injection 
site were the most commonly reported local reactions in 
vaccine and placebo recipients (figure 2; 
appendix pp 7–19). These events were less common 
among HIV-negative participants than in people with 
HIV and, in both groups, were predominantly mild or 
moderate in intensity, with moderate symptoms 
reported more often in the first 2 days after vaccination. 
Among both HIV-negative participants and people with 
HIV, there were no increases in reported local reactions 
after receiving the booster dose. Headache, joint and 
muscle pain, and weakness were the most commonly 
reported systemic reactions, occurring in almost a 
quarter of participants in the first 2 days after the 
priming dose (figure 2). Symptoms were mild or 
moderate in intensity over the first 48 h in all vaccinees. 
Fever, rigors, and sweating, lasting up to 7 days, were 
less commonly reported in HIV-negative participants 
than in people with HIV. There were 237 adverse events 
in HIV-negative participants (142 placebo; 95 vaccine) 
compared with 164 adverse events in people with HIV 
(78 placebo; 86 vaccine). The most common adverse 
event was general system disorders not elsewhere 
classified in both treatment groups in HIV-negative 
participants and people with HIV (appendix pp 20–23). 
Overall, seven serious adverse events occurred 
(appendix p 24). Six of these occurred in HIV-negative 
participants (four in those receiving the vaccine, 
two in those receiving placebo), of which five were deemed 
unrelated to the trial intervention. One HIV-negative 
participant reported a temperature of 40·5°C after the 
primary dose. However, the temperature resolved within 
1 day with paracetamol, and no reactions to booster dose 
were reported. One person with HIV who received 
placebo treatment died during the study; this death was 
deemed unlikely to be related to the trial intervention.
There were few haematological abnormalities and no 
clinically important worsening was seen in haematology 
or chemistry panels in any of the trial groups (appendix 
pp 33–34). People with HIV had mild levels of alkaline 
phosphatase elevation in both vaccine and placebo 
Figure 2: Solicited local and systemic adverse reactions in the 7 days after 
priming and booster doses of ChAdOx1 nCoV-19
Day 0 is the day of the priming dose. The severity of adverse events was graded 
as mild, moderate, or severe.
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groups throughout the trial. There were four potassium 
level increases graded as severe or higher because 
samples were haemolysed, and all subsequent blood 
draws showed normal levels of potassium.
Of the 32 participants with a positive SARS-CoV-2 
PCR test during the trial, only one (a person with 
HIV) displayed moderate COVID-19 symptoms, which 
occurred between day 28 (28 days after priming dose) and 
day 42 (14 days after booster dose; appendix p 25). The 
remaining participants with a positive SARS-
CoV-2 PCR test were asymptomatic (six HIV-negative 
participants and one person with HIV), had mild 
symptoms (eight HIV-negative participants and five people 
with HIV), or had other symptoms that did not meet the 
protocol definition of mild COVID-19 disease 
(ten HIV-negative participants and one person with HIV).
Figure 3: Immunogenicity to SARS-CoV-2 full-length spike and receptor-binding domain proteins
Analyses stratified by HIV status (A) and by SARS-CoV-2 serostatus (B) at baseline in people with HIV. Antibody responses assessed at day 0 (baseline), day 28 (post-
priming dose), and day 42 (14 days post-booster dose). Boxes denote interquartile ranges and horizontal bars denote median antibody concentration in BAU/mL. 
BAU=binding antibody unit. 
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Primary immunogenicity analyses in SARS-CoV-2 
seronegative participants included samples from 
44 HIV-negative participants (21 placebo, 23 vaccine) and 
62 people with HIV (30 placebo, 32 vaccine). Immunised 
participants showed a strong, vaccine-induced serum 
IgG response against FLS and RBD, regardless of 
HIV status, which increased with the booster dose 
(figure 3A). 28 days after the priming dose, the median 
FLS IgG GMC was 163·7 BAU/mL (95% CI 89·9–298·1) 
for people with HIV (n=36) and 112·3 BAU/mL 
(61·7–204·4) for HIV-negative participants (n=23). A 
booster response was measured at day 42, with a median 
GMC of 453·1 BAU/mL (267·4–767·7) in people with 
HIV (n=32), and 504·9 BAU/mL (337·1–756·2) in 
HIV-negative participants (n=23; appendix p 26). Similar 
IgG response patterns were seen for ChAdOx1 nCoV-19-
induced geometric mean RBD-binding IgG concen-
trations (appendix p 27). Seropositivity for either FLS 
or RBD IgG was similar in people with HIV and 
HIV-negative participants who received the vaccine. At 
day 28, seropositivity for FLS IgG was 86% (95% CI 
71·3–93·9) in people with HIV and 78% (58·1–90·3) in 
HIV-negative participants (appendix p 26).
We also assessed immunogenicity in people with 
HIV based on SARS-CoV-2 serostatus at baseline, 
excluding patients with a positive SARS-CoV-2 PCR test, 
enabling a post-hoc analysis of immune responses in 
this group after vaccination (figure 3B). The same 
analysis was not possible for the HIV-negative group 
because only three participants were SARS-CoV-2 
seropositive; although six HIV-negative participants 
tested seropositive for SARS-CoV-2, three were excluded 
because they had a positive SARS-CoV-2 PCR test at the 
time of randomi sation. At day 28, both FLS and 
RBD IgG concentrations increased substantially from 
baseline after the first dose, with modest increases seen 
by day 42 (appendix pp 28–29). The IgG GMCs after the 
priming dose of ChAdOx1-nCoV-19 in people with HIV 
who were SARS-CoV-2 seropositive at enrolment were 
18·0–29·7-times higher after the priming dose and 
6·5–6·8-times higher after the booster dose in people 
with HIV who were SARS-CoV-2 naive at baseline 
(appendix pp 28–29). When assessing cross-reactivity of 
binding antibodies to the FLS from the beta variant, 
vaccinated people with HIV and HIV-negative 
participants showed strong correlations in their ability 
to bind FLS from Asp614Gly wild-type and the 
beta variant, regardless of baseline SARS-CoV-2 
serostatus (figure 4). Corresponding plasma IgG 
antibody binding data for placebo recipients is given in 
the appendix (appendix p 35).
In the 26 HIV-negative participants vaccinated with 
ChAdOx1 nCoV-19 who were assessed for neutralisation 
activity against Asp614Gly wild-type, the GMT of 
SARS-CoV-2 neutralising antibodies strongly correlated 
with Asp614Gly wild-type antigen-specific IgG GMCs 
on days 28 and 42. Of the 25 HIV-negative, 
Figure 4: Correlation of plasma IgG antibody binding to Wuhan-1 Asp614Gly wild-type vs beta (B.1.351) full-
length spike protein in vaccine recipients
Analyses stratified by day and HIV status. OD=optical density.
1 2 3 4
Wild-type SARS-CoV-2 OD450nm Wild-type SARS-CoV-2 OD450nmWild-type SARS-CoV-2 OD450nm


























































Figure 5: Pseudovirus neutralisation responses to Wuhan-1 Asp614Gly wild-type on day 42 in vaccinees
Samples below the limit of detection are not shown. Boxes denote interquartile ranges, and horizontal bars denote 
neutralisation ID50. ID50=inhibitory dilution (50%). RBD=receptor-binding domain.
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SARS-CoV-2 baseline-seronegative participants, 
two mounted neutralising responses at day 0, with GMT 
neutralisation activity of inhibitory dilution 50% 
(ID50) 31·2 (95% CI 1·9–526·6), and 13 (59%) of 
22 participants mounted neutralising responses of 
ID50 135·0 (54·5–334·2) by day 28. Neither of the 
two participants who showed neutralisation activity at 
day 0 subsequently showed an increase of at least two 
times at day 28. At day 42, 20 participants mounted 
neutralising responses with GMT neutralising activity 
ID50 316·4 (184·8–541·8; appendix p 30).
Using an MLV-based neutralisation assay, we also 
assessed neutralising antibody activity against Asp614Gly 
wild-type in all samples from people with HIV who were 
RBD seropositive at day 42. Of these, data were obtained 
for 33 (65%) samples. Of the 18 people with HIV who 
were RBD seronegative at baseline and received 
the vaccine, 17 mounted neutralising responses, with 
point estimate GMT neutralisation activity of ID50 151·5 
(95% CI 954·8–419·0) being lower than that of 
18 HIV-negative participants who were RBD seronegative 
at baseline with neutralisation activity of ID50 of 394·2 
(242·0–642·1; figure 5); albeit with overlapping 95% CI.
Among 13 HIV-negative vaccinees with neutralisation 
activity against Asp614Gly wild-type, only two participants 
retained activity against the beta variant. By contrast, 
among 20 people with HIV with neutralisation activity 
against Asp614Gly wild-type, ten vaccinees retained activity 
against the beta variant, eight of whom were seropositive 
for SARS-CoV-2 at baseline (appendix p 36). Corresponding 
neutralisation activity in people with HIV who received the 
placebo is provided in the appendix (p 37).
Discussion
Results of this interim phase 1B/2A analysis, show that 
two doses of ChAdOx1 nCoV-19 were well tolerated, with 
similar FLS-binding and RBD-binding IgG and SARS-
CoV-2 neutralising response patterns in people with HIV 
and HIV-negative SARS-CoV-2-naive participants after 
priming and booster doses of the vaccine. Our findings are 
similar to previously reported immunogenicity of this 
vaccine across all adult age groups.4
Antibody responses to FLS and RBD viral proteins 
induced by each dose were also seen in people with HIV 
who had previously been exposed to SARS-CoV-2. 
Notably, previous infection with SARS-CoV-2 in people 
with HIV was associated with robust immune responses 
after the first dose of ChAdOx1 nCoV-19, with GMCs 
exceeding by 6·49–6·84 times those seen post-booster 
dose in vaccine recipients who were seronegative at 
enrolment, as similarly reported for mRNA vaccines, 
BNT162b2 (Pfizer–BioNTech) and mRNA-1273 (Moderna) 
in HIV-negative participants.21
In our trial, development of neutralising titres against 
the Asp614Gly wild-type strain after priming and booster 
doses of ChAdOx1 nCoV-19 correlated with antibody 
responses to FLS and RBD viral antigens in HIV-negative 
participants and in people with HIV. Taken together, 
these findings suggest that vaccination with ChAdOx1 
nCoV-19 might consolidate the immune response and 
drive long-term immune memory, providing a protective 
benefit to this population against the ancestral strain, 
regardless of previous SARS-CoV-2 exposure. Neutralising 
antibodies have been implicated as correlates of pro-
tection from COVID-19 in preclinical challenge studies22 
and, in a previous clinical trial, neutralising antibodies 
developed against the Asp614Gly wild-type strain in more 
than 99% of participants after vaccination with 
ChAdOx1 nCoV-19, with higher levels in boosted than in 
non-boosted groups.4 However, to date, no correlates of 
protection have been defined from clinical COVID-19 
vaccine studies.
The majority of adverse events reported in people 
with HIV and HIV-negative participants were mild 
or moderate in intensity, which is consistent with 
the reported safety profile of ChAdOx1 nCoV-19.1,6,14 
Reactogenicity, which we assessed 7 days after the 
priming and booster doses of vaccine, was lower in 
HIV-negative participants than in people with HIV, with 
symptoms that were predominantly mild or moderate in 
intensity. In both populations, fewer adverse events were 
reported after the booster dose than after the priming 
dose and no clinically important worsening was seen in 
haematology or chemistry panels compared with placebo.
People with HIV have a greater risk for fatal outcome 
upon COVID-19-related admission to hospital8 with 
higher associations in people of Black ethnicity than in 
non-Black individuals.23 In South Africa, HIV infection 
has also been associated with an increased risk of death 
from COVID-19, irrespective of HIV-1 viral load and 
immunosuppression.24
Conducting vaccine trials in Africa is vital to ensure 
that COVID-19 vaccines will be effective in this setting, 
particularly given the burden of HIV in sub-Saharan 
Africa13 and the emergence of variants such as the 
beta variant.5 In the overall analysis of the present 
phase 1B/2A trial, published elsewhere,6 the two-dose 
regimen of ChAdOx1 nCoV-19 did not show protection 
against non-hospitalised mild to moderate COVID-19 
after infection with the beta variant in young HIV-negative 
adults in South Africa. In those participants, ChAdOx1 
nCoV-19 induced strong neutralising antibodies 28 days 
after the first dose, which increased after booster dose 
was given 21–35 days later, yet neutralising activity was 
reduced or undetected against the beta variant.6 Although 
efficacy against severe disease caused by beta could 
not be assessed, in a preclinical study in hamsters, 
vaccination with ChAdOx1 nCoV-19 protected against 
pneumonia when animals were challenged with beta, 
which is consistent with protection against severe 
disease but not mild disease restricted to the upper 
respiratory tract.25
In this interim analysis, we show that, in people with 
HIV and HIV-negative vaccinees, vaccine-elicited 
Articles
www.thelancet.com/hiv   Vol 8   September 2021 e579
binding antibodies to FLS show high level cross-reactivity 
for the beta variant. These results are similar to previously 
published results from convalescent donor plasma.17,26 
Binding antibodies might contribute to Fc effector 
functions, which have been implicated in preventing 
severe disease in convalescent donors. Whether this 
effect is also true of cross-reactive vaccine-elicited 
binding antibodies remains to be determined.
Furthermore, in those vaccinated people with HIV who 
developed neutralising responses to Asp614Gly wild-
type, neutralisation against the beta variant was retained 
in 50% of vaccinated participants, 80% of whom were 
RBD IgG seropositive at baseline, and in whom 
ChAdOx1 nCoV-19 induced high neutralising antibody 
titres against the original Asp614Gly wild-type strain. 
These observations suggest that ChAdOx1 nCoV-19 
vaccination in settings with a high prevalence of 
SARS-CoV-2 infection due to the ancestral virus could 
result in some protection, even against mild to moderate 
COVID-19 caused by the beta variant.
Our study has some limitations. First, the small sample 
size of HIV-negative participants who were SARS-CoV-2 
seropositive, which precluded comparisons between 
SARS-CoV-2 seropositive participants in both groups. 
Second, experiments on cell-mediated immune responses 
in participants have not yet been completed. Previous 
studies have shown that spike-specific T-cell responses 
are induced by ChAdOx1 nCoV-19 in vaccine recipients 
from 7 days after the priming dose.4 Third, owing to the 
phase 1B/2A design of this trial, a relatively risk-averse 
group of people with HIV receiving ART and who were 
virally suppressed with CD4 counts of more than 500 cells 
per µL were included, limiting its generalisability to the 
overall population of people with HIV. Finally, ART can 
interfere with the performance of neutralisation assays, 
which explains the relatively low number of people with 
HIV whose sera provided neutralising antibody data in 
this trial.
Given the prevalence of emerging SARS-CoV-2 variants 
of concern, further trials in people with HIV and in 
South Africa, which include analyses of cellular responses, 
are warranted, as are additional studies to correlate 
vaccine-induced immunogenicity with COVID-19 
protection. However, the findings from this interim 
analysis of administration of a COVID-19 vaccine specific 
to people with HIV, and specific to Africa, show favourable 
safety and immunogenicity of ChAdOx1 nCoV-19. Our 
findings also suggest that previous exposure to the 
ancestral SARS-CoV-2 virus, Asp614Gly wild-type, in 
people with HIV might result in a heightened immune 
response, including some preservation of neutralising 
antibody activity against the beta variant.
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